Using Nigella Sativa Oil to Help Treat Pneumonia in Children
Role of Nigella Sativa Oil as an Adjuvant Therapy in the Treatment of Pediatric Pneumonia
This study is testing if adding Nigella Sativa oil to standard treatments can help children with pneumonia recover faster and shorten their hospital stay.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 104 (estimated) |
| Ages | 2 Months to 18 Years |
| Sex | All |
| Sponsor | Tanta University Academic / other |
| Locations | 1 site (Tanta, Gharbia) |
| Trial ID | NCT05952102 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of oral Nigella Sativa oil as an additional treatment for pediatric pneumonia alongside standard antibiotics and supportive care. The primary focus is on measuring the duration of pneumonia symptoms and hospital stay for children admitted with lower respiratory tract infections. The study aims to determine if the immunomodulatory properties of Nigella Sativa can enhance recovery outcomes in hospitalized children. By assessing both clinical manifestations and potential complications, the research seeks to provide a comprehensive understanding of the oil's therapeutic benefits.
Who should consider this trial
Good fit: Ideal candidates are hospitalized children exhibiting signs of lower respiratory tract infections and confirmed pneumonia through chest x-ray.
Not a fit: Children with immunodeficiencies, chronic lung diseases, or other serious underlying conditions may not benefit from this treatment.
Why it matters
Potential benefit: If successful, this treatment could improve recovery times and reduce hospital stays for children suffering from pneumonia.
How similar studies have performed: While the use of Nigella Sativa has been explored in various contexts, this specific application in pediatric pneumonia is relatively novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Signs and symptoms of lower respiratory tract infections (LRTI) (LRTI was defined as ≥ 1 of the following: new or different cough or sputum production, chest pain, dyspnea, tachypnea, or abnormal auscultatory findings). * Focal findings on chest x-ray indicating pneumonia. Exclusion Criteria: * Children with immunodeficiency, chronic lung disease, malignancy, congenital lung anomalies, underlying disorder impacting respiration i.e. genetic, metabolic, neuromuscular disorders....etc, children with CHD affecting the pulmonary blood flow
Where this trial is running
Tanta, Gharbia
- Faculty of Medicine — Tanta, Gharbia, Egypt (Recruiting)
Study contacts
- Study coordinator: Rehab Zaki Elmeazawy, MD
- Email: rehab.elmeazawy@med.tanta.edu.eg
- Phone: 01004815280
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.